BioCentury | May 11, 2017
Company News

Horizon acquires rare eye disease therapy

...IGF1R) has breakthrough therapy and Orphan Drug designations from FDA. River Vision was founded by Narrow River Management L.P....
BioCentury | May 11, 2017
Clinical News

Teprotumumab meets in Phase II thyroid eye disease trial

...2H19. Earlier this month, Horizon acquired River Vision Development Corp. , which was founded by Narrow River Management L.P....
BioCentury | May 8, 2017
Company News

Horizon acquires rare eye disease therapy

...which has breakthrough therapy and Orphan Drug designations from FDA. River Vision was founded by Narrow River Management L.P....
BioCentury | Jun 17, 2013
Clinical News

Teprotumumab regulatory update

...trial in about 84 patients with active thyroid eye disease. River Vision was founded by Narrow River Management L.P....
Items per page:
1 - 4 of 4
BioCentury | May 11, 2017
Company News

Horizon acquires rare eye disease therapy

...IGF1R) has breakthrough therapy and Orphan Drug designations from FDA. River Vision was founded by Narrow River Management L.P....
BioCentury | May 11, 2017
Clinical News

Teprotumumab meets in Phase II thyroid eye disease trial

...2H19. Earlier this month, Horizon acquired River Vision Development Corp. , which was founded by Narrow River Management L.P....
BioCentury | May 8, 2017
Company News

Horizon acquires rare eye disease therapy

...which has breakthrough therapy and Orphan Drug designations from FDA. River Vision was founded by Narrow River Management L.P....
BioCentury | Jun 17, 2013
Clinical News

Teprotumumab regulatory update

...trial in about 84 patients with active thyroid eye disease. River Vision was founded by Narrow River Management L.P....
Items per page:
1 - 4 of 4